Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06641037 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3866288 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT06641037 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 15 participants.
The verdict
NCT06641037, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how well LY3866288 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3866288 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 9 weeks including screening.
Interventions
- DRUG LY3866288
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-10-17 |
| Est. Completion | 2024-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06641037
The ClinicalTrials.gov registry entry for NCT06641037 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY3866288 is the first listed.
NCT06641037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06641037 about?
NCT06641037 is a clinical study titled "A Study of LY3866288 in Healthy Participants". The purpose of this study is to evaluate how well LY3866288 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3866288 gets into the bloodstream and how long it takes the body to eliminat...
What is the current status of trial NCT06641037?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-10-17. Estimated completion is 2024-12-02.
What interventions are being tested in trial NCT06641037?
The interventions under investigation include: LY3866288 (DRUG).
Who is sponsoring clinical trial NCT06641037?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.